scholarly journals Leptomeningeal myelomatosis in previously treated high-risk kappa light chain multiple myeloma: case report and literature review

2011 ◽  
pp. 9 ◽  
Author(s):  
Maro Ohanian ◽  
Alaly ◽  
Samuel ◽  
Christian Cable ◽  
Kathleen Halka
Keyword(s):  
Multiple Myeloma ◽  
Case Report ◽  
High Risk ◽  
Literature Review ◽  
Light Chain ◽  
Kappa Light Chain ◽  
Previously Treated

scholarly journals Russell Body Typhlitis: A Case Report and Literature Review

2021 ◽  
pp. 106689692110082
Author(s):  
Sarah Al-Rawaf ◽  
Salem Alowami ◽  
Robert Riddell ◽  
Asghar Naqvi
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Light Chain ◽  
Plasma Cells ◽  
Gastrointestinal Disease ◽  
English Literature ◽  
The Other ◽  
Tubulovillous Adenoma ◽  
Inflammatory Polyp ◽  
Intracytoplasmic Inclusions

Russell bodies are accumulation of immunoglobulin in plasma cells forming intracytoplasmic inclusions. Russell body colitis is rare with only 3 cases described in the English literature up to date. We report a 78-year-old male with cirrhosis showing prominent cecal infiltration of Russell body containing plasma cells. Plasma cells showed no nuclear atypia or mitoses, and no evidence of light chain restriction. In this article, we report a fourth case of Russell body colitis, that is unique in being localized to the cecum in contrast to the other 3, 1 of which was in an inflammatory polyp in the sigmoid colon, 1 in a rectal tubulovillous adenoma and 1 as part of diffuse gastrointestinal disease. This is therefore the first report of localized Russell body typhlitis, occurring in a cirrhotic patient in whom an adjacent erosion was likely nonsteroidal anti-inflammatory drug-associated, a combination that may have facilitated the formation of Russell bodies.

scholarly journals Revitalizing previously treated teeth with open apices: a case report and a literature review

2021 ◽  
Author(s):  
A. Nosrat ◽  
B. Bolhari ◽  
S. Saber Tahan ◽  
O. Dianat ◽  
P.M.H. Dummer
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Previously Treated ◽  
Open Apices

Multiple myeloma and chronic myelogenous leukemia: a case report with literature review

1993 ◽  
Vol 34 (3) ◽  
pp. 293 ◽  
Author(s):  
Philip J. Klenn ◽  
Bong H. Hyun ◽  
Young Hee Lee ◽  
Wen Yu Zheng
Keyword(s):  
Multiple Myeloma ◽  
Case Report ◽  
Literature Review ◽  
Chronic Myelogenous Leukemia ◽  
Myelogenous Leukemia

scholarly journals Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma

2019 ◽  
Vol 3 (5) ◽  
pp. 744-750 ◽  
Author(s):  
Nidhi Tandon ◽  
Surbhi Sidana ◽  
S. Vincent Rajkumar ◽  
Morie A. Gertz ◽  
Francis K. Buadi ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
High Risk ◽  
Light Chain ◽  
Progression Free Survival ◽  
Early Response ◽  
Stage Iii ◽  
Newly Diagnosed ◽  
Best Response ◽  
Light Chain Disease ◽  
The Impact

Abstract We evaluated the impact of achieving a rapid response in 840 newly diagnosed multiple myeloma patients from 2004 to 2015. Rates of very good partial response (VGPR) or better were 29% (240/840) after 2 cycles of treatment, 42% (350/840) after 4 cycles of treatment, and 66% (552/840) as best response. Early responders after 2 cycles of treatment had higher rates of light chain disease, anemia, renal failure, International Staging System (ISS) stage III disease, and high-risk cytogenetics, especially t(4;14), and were more likely to have received triplet therapy and undergo transplant. Median progression-free survival (PFS) and overall survival (OS) were not different among patients with ≥VGPR and <VGPR after 2 cycles (PFS, 28 vs 30 months, P = .6; OS, 78 vs 96 months, P = .1) and 4 cycles (PFS, 31 vs 29 months; OS, 89 vs 91 months, P = .9), although both were improved, with ≥VGPR as best response (PFS, 33 vs 22 months, P < .001; OS, 102 vs 77 months, P = .003). On multivariate analysis stratified by transplant status, achievement of ≥VGPR after 2 cycles was not associated with improved PFS (hazard ratio [95% confidence interval]; transplant cohort, 1.1 [0.7-1.6]; nontransplant cohort, 1.2 [0.8-1.7]) or OS (transplant cohort, 1.6 [0.9-2.9]; nontransplant cohort, 1.5 [1.0-2.4]). Covariates in the model included high-risk cytogenetics, ISS stage III, triplet therapy, creatinine ≥2 mg/dL, light chain disease, and age. Although patients with high-risk disease are more likely to achieve early response, a rapid achievement of a deep response by itself does not affect long-term outcomes.

Sign in / Sign up

Export Citation Format

Share Document